Lobucavir has been used in trials studying the treatment of HIV Infections and Cytomegalovirus Infections.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Deferasirox | The serum concentration of Lobucavir can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Lobucavir can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Lobucavir can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Lobucavir can be decreased when it is combined with Teriflunomide. |
| Regadenoson | Lobucavir may decrease effectiveness of Regadenoson as a diagnostic agent. |
| Adalimumab | The serum concentration of Lobucavir can be decreased when it is combined with Adalimumab. |
| Adenosine | The therapeutic efficacy of Adenosine can be decreased when used in combination with Lobucavir. |
| Allopurinol | The serum concentration of Lobucavir can be increased when it is combined with Allopurinol. |
| Carbamazepine | The serum concentration of Lobucavir can be decreased when it is combined with Carbamazepine. |
| Cimetidine | The metabolism of Lobucavir can be decreased when combined with Cimetidine. |
| Disulfiram | The serum concentration of Lobucavir can be increased when it is combined with Disulfiram. |
| Febuxostat | The serum concentration of the active metabolites of Lobucavir can be increased when Lobucavir is used in combination with Febuxostat. |
| Fluvoxamine | The metabolism of Lobucavir can be decreased when combined with Fluvoxamine. |
| Formoterol | The risk or severity of hypokalemia can be increased when Lobucavir is combined with Formoterol. |
| Indacaterol | The risk or severity of adverse effects can be increased when Lobucavir is combined with Indacaterol. |
| Isoniazid | The serum concentration of Lobucavir can be increased when it is combined with Isoniazid. |
| Lithium citrate | The serum concentration of Lithium citrate can be decreased when it is combined with Lobucavir. |
| Lithium carbonate | The serum concentration of Lithium carbonate can be decreased when it is combined with Lobucavir. |
| Lithium hydroxide | The serum concentration of Lithium hydroxide can be decreased when it is combined with Lobucavir. |
| Mexiletine | The metabolism of Lobucavir can be decreased when combined with Mexiletine. |
| Olodaterol | Lobucavir may increase the hyperkalemic activities of Olodaterol. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be decreased when used in combination with Lobucavir. |
| Pentoxifylline | The serum concentration of Lobucavir can be increased when it is combined with Pentoxifylline. |
| Phenytoin | The serum concentration of Lobucavir can be decreased when it is combined with Phenytoin. |
| Fosphenytoin | The serum concentration of Lobucavir can be decreased when it is combined with Fosphenytoin. |
| Propafenone | The serum concentration of Lobucavir can be increased when it is combined with Propafenone. |
| Quinine | The serum concentration of Lobucavir can be increased when it is combined with Quinine. |
| Quinidine | The serum concentration of Lobucavir can be increased when it is combined with Quinidine. |
| Riociguat | Lobucavir may increase the hypotensive activities of Riociguat. |
| Thiabendazole | The metabolism of Lobucavir can be decreased when combined with Thiabendazole. |
| Ticlopidine | The metabolism of Lobucavir can be decreased when combined with Ticlopidine. |
| Zafirlukast | The serum concentration of Zafirlukast can be decreased when it is combined with Lobucavir. |
| Probenecid | The serum concentration of Lobucavir can be increased when it is combined with Probenecid. |
| Abiraterone | The serum concentration of Lobucavir can be increased when it is combined with Abiraterone. |
| Isoprenaline | The serum concentration of Lobucavir can be decreased when it is combined with Isoprenaline. |
| Cyproterone acetate | The metabolism of Lobucavir can be increased when combined with Cyproterone acetate. |
| Amphetamine | The risk or severity of adverse effects can be increased when Amphetamine is combined with Lobucavir. |
| Phentermine | The risk or severity of adverse effects can be increased when Phentermine is combined with Lobucavir. |
| Midodrine | The risk or severity of adverse effects can be increased when Midodrine is combined with Lobucavir. |
| Norepinephrine | The risk or severity of adverse effects can be increased when Norepinephrine is combined with Lobucavir. |
| Phenylephrine | The risk or severity of adverse effects can be increased when Phenylephrine is combined with Lobucavir. |
| Phenylpropanolamine | The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Lobucavir. |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with Lobucavir. |
| Metaraminol | The risk or severity of adverse effects can be increased when Metaraminol is combined with Lobucavir. |
| Epinephrine | The risk or severity of adverse effects can be increased when Epinephrine is combined with Lobucavir. |
| Methoxamine | The risk or severity of adverse effects can be increased when Methoxamine is combined with Lobucavir. |
| Orciprenaline | The risk or severity of adverse effects can be increased when Orciprenaline is combined with Lobucavir. |
| Phenmetrazine | The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Lobucavir. |
| Dobutamine | The risk or severity of adverse effects can be increased when Dobutamine is combined with Lobucavir. |
| Pseudoephedrine | The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lobucavir. |
| Benzphetamine | The risk or severity of adverse effects can be increased when Benzphetamine is combined with Lobucavir. |
| Ritodrine | The risk or severity of adverse effects can be increased when Ritodrine is combined with Lobucavir. |
| Terbutaline | The risk or severity of adverse effects can be increased when Terbutaline is combined with Lobucavir. |
| Oxymetazoline | The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lobucavir. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Diethylpropion is combined with Lobucavir. |
| Dopamine | The risk or severity of adverse effects can be increased when Dopamine is combined with Lobucavir. |
| Acebutolol | The risk or severity of adverse effects can be increased when Acebutolol is combined with Lobucavir. |
| Lisdexamfetamine | The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Lobucavir. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with Lobucavir. |
| Ephedrine | The risk or severity of adverse effects can be increased when Ephedrine is combined with Lobucavir. |
| Mephentermine | The risk or severity of adverse effects can be increased when Mephentermine is combined with Lobucavir. |
| Procaterol | The risk or severity of adverse effects can be increased when Procaterol is combined with Lobucavir. |
| Clenbuterol | The risk or severity of adverse effects can be increased when Clenbuterol is combined with Lobucavir. |
| MMDA | The risk or severity of adverse effects can be increased when MMDA is combined with Lobucavir. |
| Midomafetamine | The risk or severity of adverse effects can be increased when Midomafetamine is combined with Lobucavir. |
| 2,5-Dimethoxy-4-ethylamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Lobucavir. |
| 4-Bromo-2,5-dimethoxyamphetamine | The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Lobucavir. |
| Tenamfetamine | The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Lobucavir. |
| Chlorphentermine | The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Lobucavir. |
| Methylenedioxyethamphetamine | The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Lobucavir. |
| Dextroamphetamine | The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Lobucavir. |
| Metamfetamine | The risk or severity of adverse effects can be increased when Metamfetamine is combined with Lobucavir. |
| Celiprolol | The risk or severity of adverse effects can be increased when Celiprolol is combined with Lobucavir. |
| Nylidrin | The risk or severity of adverse effects can be increased when Nylidrin is combined with Lobucavir. |
| Tetryzoline | The risk or severity of adverse effects can be increased when Tetryzoline is combined with Lobucavir. |
| Tyramine | The risk or severity of adverse effects can be increased when Tyramine is combined with Lobucavir. |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Lobucavir. |
| Etilefrine | The risk or severity of adverse effects can be increased when Etilefrine is combined with Lobucavir. |
| Synephrine | The risk or severity of adverse effects can be increased when Synephrine is combined with Lobucavir. |
| Hydroxyamphetamine | The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Lobucavir. |
| Iofetamine I-123 | The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Lobucavir. |
| Racepinephrine | The risk or severity of adverse effects can be increased when Racepinephrine is combined with Lobucavir. |
| Ritobegron | The risk or severity of adverse effects can be increased when Ritobegron is combined with Lobucavir. |
| Bucindolol | The risk or severity of adverse effects can be increased when Bucindolol is combined with Lobucavir. |
| Tramazoline | The risk or severity of adverse effects can be increased when Tramazoline is combined with Lobucavir. |
| Mephedrone | The risk or severity of adverse effects can be increased when Mephedrone is combined with Lobucavir. |
| Fenozolone | The risk or severity of adverse effects can be increased when Fenozolone is combined with Lobucavir. |
| Methoxyphenamine | The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Lobucavir. |
| Tretoquinol | The risk or severity of adverse effects can be increased when Tretoquinol is combined with Lobucavir. |
| Gepefrine | The risk or severity of adverse effects can be increased when Gepefrine is combined with Lobucavir. |
| Epanolol | The risk or severity of adverse effects can be increased when Epanolol is combined with Lobucavir. |
| Prenalterol | The risk or severity of adverse effects can be increased when Prenalterol is combined with Lobucavir. |
| Mefenorex | The risk or severity of adverse effects can be increased when Mefenorex is combined with Lobucavir. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Lobucavir. |
| Esmolol | The risk or severity of adverse effects can be increased when Esmolol is combined with Lobucavir. |
| Betaxolol | The risk or severity of adverse effects can be increased when Betaxolol is combined with Lobucavir. |
| Metoprolol | The risk or severity of adverse effects can be increased when Metoprolol is combined with Lobucavir. |
| Atenolol | The risk or severity of adverse effects can be increased when Atenolol is combined with Lobucavir. |
| Timolol | The risk or severity of adverse effects can be increased when Timolol is combined with Lobucavir. |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with Lobucavir. |